Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Biogen gains as analysts raise numbers after Roche's gantenerumab failure

Published 11/14/2022, 08:01 AM
Updated 11/14/2022, 08:12 AM
© Reuters Biogen (BIIB) gains as analysts raise numbers after Roche's Gantenerumab failure

By Senad Karaahmetovioc

Biogen (NASDAQ:BIIB) shares are trading more than 5% higher in pre-market Monday after rival Roche (OTC:RHHBY) presented disappointing results for its Alzheimer’s treatment gantenerumab.

Much-awaited results showed gantenerumab failed its phase 3 trial. While the drug was well tolerated, the level of beta-amyloid was lower than expected.

RBC analysts believe the trial results “remove a competitor which could have had an advantage of a more convenient formulation.”

“We think that it also raises a slight risk as lecanemab is the only drug that has worked so far by targeting the amyloid pathway, and we think FDA may add more scrutiny to the Ph.III data from the CLARITY AD to understand why the study worked,” the analysts said in a client note.

Stifel analysts are more positive as they raised the price target on Biogen to $331 per share, up from the prior $299 after removing any share from Roche's gantenerumab in their Alzheimer's market model.

“We believe the gant failure further increases the likelihood that lecanemab--on the back of strong efficacy data and best-in-class safety data--could be the leading anti-amyloid therapy within a $10B+ market,” they wrote in a note.

Wolfe analysts added that the trial failure is a boost for Biogen and Eli Lilly (NYSE:LLY). For Roche, this is a clear setback although “not one that was totally unexpected.”

At 08:00 ET (13:00 GMT), Roche (SIX:RO) shares are down 4.5% in European trading. LLY shares are up about 1.8% in U.S. pre-market trading.


Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.